STAMFORD, Conn.—FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other market-leading oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities. The unveiling at booth #3063 during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting marks Fujifilm’s entry into the CT market, expanding its end-to-end diagnostic imaging product portfolio which is recognized for exceptional imaging at low dose.

At the 60th annual meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 at the Henry B. Gonzalez Convention Center in San Antonio, Siemens Healthineers unveils the MAGNETOM RT Pro edition for MAGNETOM Sola – a version of the company’s new 1.5 Tesla (1.5T) magnetic resonance imaging (MRI) scanner that is designed for assistance in radiation therapy (RT) treatment planning. In addition to BioMatrix technology, which addresses patients’ anatomical and physiological differences to overcome unwanted exam variability, the new scanner includes hardware and software that supports optimal treatment planning.

Prominent medical societies have issued new clinical guidelines, Thursday, Oct. 11, recommending physicians use external beam radiation therapy (EBRT) to treat men with early-stage prostate cancer.

On Wednesday, Oct. 10, the Society of Breast Imaging (SBI) and Oxford University Press (OUP) announced a partnership to publish the Journal of Breast Imaging (JBI)—the first peer-reviewed journal dedicated to breast imaging.

Just 39 percent of healthcare organizations and providers are confident in their medical device security, according to report by KLAS, College of Healthcare Information Management Executives (CHIMES) and the Association for Executives in Healthcare Information Security (AEHIS).

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.

Performing coronary CT angiography (CCTA) in addition to standard care is associated with a lower risk of death from coronary artery disease than standard care alone, according to research published in the New England Journal of Medicine.